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Diarrheal illness is responsible for over a quarter of all deaths in children under 5 years of 
age in sub-Saharan Africa and South Asia. Recent findings have identified the parasite 
Cryptosporidium as a contributor to enteric disease. We examined 9,348 cases and 
13,128 controls from the Global Enteric Multicenter Study to assess whether 
Cryptosporidium interacted with co-occurring pathogens based on adjusted odds of 
moderate-to-severe diarrhea (MSD). Cryptosporidium was found to interact negatively 
with Shigella spp., with multiplicative interaction score of 0.16 (95% CI: 0.07 to 0.37, p-
value=0.000), and an additive interaction score of -9.81 (95% CI: -13.61 to -6.01, p-
value=0.000). Cryptosporidium also interacted negatively with Aeromonas spp., 
Adenovirus, Norovirus, and Astrovirus with marginal significance. Odds of MSD for 
Cryptosporidium co-infection with Shigella spp., Aeromonas spp., Adenovirus, 
Norovirus, or Astrovirus are lower than odds of MSD with either organism alone. This 
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Chapter 1: Introduction 
Diarrheal Disease in the Developing World 
Diarrhea is the second leading cause of death in young children worldwide [1]. 
Diarrheal illness is responsible for 25-30% of all deaths in children under 5 years of age 
in sub-Saharan Africa and South Asia [2]. With time and resources, diarrhea in children 
is easily treatable, but in the developing world, malnutrition and healthcare access issues 
potentiate its harm. While the instance of diarrhea for a young individual is in itself 
unpleasant and life threatening, not to mention a potential economic strain on the family, 
the impacts of the illness do not necessarily end when the clinical symptoms subside. 
Diarrhea in children is well associated with long term developmental impacts including 
growth stunting, cognitive impairments, changes in school performance, and work life 
productivity [3–10]. These long term sequelae, malnutrition, and risk of enteric disease 
are cyclically linked, making diarrhea an extremely complex public health issue.  
Enteric diseases are closely linked to environmental interactions (on a microbial 
scale upwards), and as such cannot easily be quantified according to a linear pathogen-to-
disease relationship. Putative pathogens are not necessarily detectable in all instances of 
diarrhea: 27% of moderate-to-severe diarrhea (MSD) cases had no identifiable pathogen 
in recent findings [11].  Pathogen detection also doesn’t strictly translate to disease: 72% 
of healthy controls in the same study had one or more pathogens detectable [11]. 
Asymptomatic infection is a public health concern in its own right, as infection with 
enteric pathogens – regardless of diarrhea outcome- is associated with environmental 
enteropathy: subtle changes in the intestinal composition and gut microbiota that can 
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impact nutrient intake and enteric illness risk long term [12,13]. These complexities limit 
public health understanding of the scope and burden of enteric illness. 
Cryptosporidium as an Emerging Concern 
Among the many microorganisms associated with diarrhea in children is 
Cryptosporidium spp. Public health awareness of the burden and impact of 
Cryptosporidium has veritably exploded in the past three years following the publication 
of two landmark international studies: the Global Enteric Multicenter Study (GEMS) and 
MAL-ED cohort study [14,15]. While it cannot be said that the protozoan is an emerging 
infectious disease in terms of incidence or geographic distribution, these recent findings 
do for the first time illuminate how broad its impact may be. Bartelt in 2013 dubbed 
Cryptosporidium spp., among others, a “Neglected Enteric Parasite” (NEP), and called on 
the World Health Organization (WHO) to reconsider the protozoan for its Neglected 
Disease Initiatives [12]. While it is not now a WHO Neglected Tropical Disease (NTD), 
it is on the NTD list considered by the Public Library of Science.  
The new information on the scope of Cryptosporidium-associated diarrhea is 
particularly concerning because Cryptosporidial diarrhea is associated with an array of 
complex health effects beyond clinical diarrhea itself. While diarrhea is in general 
associated with developmental delay, as mentioned earlier, this is especially true for 
longer periods of diarrhea [3–6]. Cryptosporidium is strongly associated with prolonged 
episodes of diarrhea: it was the leading pathogen linked to prolonged symptoms in 
GEMS, and is associated with diarrheal episodes of greater than 7 days in a number of 
studies [4,6,11,16,17]. Cryptosporidium is linked to especially prolonged cases of 
diarrhea, and these are most harmful to child development. It follows that 
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Cryptosporidium has been thoroughly associated with developmental inhibition in 
children [7,17–26]. This strong link between Cryptosporidium and increased morbidity 
associated with diarrhea, in combination with the new reports of its high prevalence in 
children of the developing world, illustrates a daunting global health challenge. This calls 
for increased research into Cryptosporidium-induced diarrheal etiology.    
Polymicrobial Enteric Infections 
Along with the recent methodological advancements has been an increase in 
reports of polymicrobial infections in enteric illness studies. Microbial quantification 
techniques now available allow for the detection of a large range of pathogenic and non-
pathogenic organisms, and the analytical capacity to process this information [27,28]. 
NEPs like Cryptosporidium are among the organisms whose detection is now far easier 
and more accurate because of these advances [29]. Polymicrobial infections in diarrhea 
have long been recognized, but now reflect more sensitive and inclusive diagnostics. A 
number of epidemiological studies have identified polymicrobial infections associated 
with diarrhea in study populations throughout the world [30–37]. In the GEMS, two or 
more putative pathogens were detected in 45% of children with MSD, and 32% of 
controls [11]. This finding is mirrored by more recent results from the MAL-ED cohort 
study, in which two or more pathogens were identified in 41.0% and 29.0% of stools for 
cases and controls, respectively [38]. Though the epidemiology of polymicrobial diarrhea 




This project explores the possible impacts of co-infection by Cryptosporidium 
with other putative enteric pathogens on diarrheal outcomes in the GEMS case-control 
study. Co-infecting organisms may interact to worsen disease outcomes relative to single 
infections, and understanding this interaction if present would help inform intervention 
strategies for diarrheal disease control. Cryptosporidium is a particularly harmful enteric 
pathogen, and it is as yet unclear how this morbidity is modulated.  
Objective: Using GEMS data, compare microbial identity data from case and 
control stools to evaluate whether Cryptosporidium interacts with other 
microorganisms, and do so in a way that is replicable for future work. 
Hypothesis: Children are at higher risk of moderate-to-severe diarrhea if co-
infected with Cryptosporidium and another organism than they are if infected 
















Chapter 2: Background 
Cryptosporidium spp. and Cryptosporidiosis 
Species and Disease Background 
 Cryptosporidium spp. is a ubiquitous apicomplexan monocellular protist with a 
global geographic distribution. An important veterinary microbe, it was first reported as a 
human pathogen in a 1976 case report of severe diarrhea in an immunocompromised 
patient [39]. It is now recognized as a significant threat to immunocompromised 
individuals and a major contributor to the global burden of diarrhea [40–42].  Many of 
the Cryptosporidium species are known to cause human disease, but the most prominent 
are Cryptosporidium parvum and Cryptosporidium homini [43]. Cryptosporidium spp.  is 
environmentally hardy, resistant to chlorination, and can harbor in a number of 
mammalian reservoirs, including humans, in perpetuity[44]. Cryptosporidium may be 
waterborne, foodborne, transmitted via oral-fecal contact, and is possibly capable of 
respiratory transmission [41]. Symptoms of Cryptosporidiosis are diarrhea, dehydration, 
nausea, vomiting, and weight loss though most individuals with detectable 
Cryptosporidium infections are asymptomatic [44].  
Epidemiology 
Heterogeneous study populations and findings have long limited epidemiological 
understanding of the global burden of Cryptosporidium-associated diarrhea. A small 
number of studies have indicated the parasite as a potentially important cause of enteric 
disease in select populations, and these have recently been reaffirmed in the two goliath 
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international studies, GEMS and MAL-ED. In GEMS, the parasite was the second 
leading cause of moderate-to-severe diarrhea in infants at five of seven sites in sub-
Saharan Africa and South Asia, and the overall fraction of illness attributable to 
Cryptosporidium at all sites was far higher than anticipated [11]. In MAL-ED, it was the 
fifth-leading cause of diarrhea in subjects in the first year of life [38]. These studies are 
the most comprehensive look into diarrheal disease etiology due to their global scope, 
unprecedented sample sizes, and use of up-to-date diagnostic microbiologic methods.   
In GEMS, the mortality associated with Cryptosporidium in cases was 3.0%, and 
4.0% for subjects aged 0-11 months and 12-23 months, respectively, with hazard ratios of 
1.2 and 2.6 relative to matched no-pathogen controls, respectively [11].  As mentioned 
earlier, Cryptosporidium is also associated with prolonged diarrheal episodes 
[4,6,11,16,17], and long term morbidity and developmental inhibition [7,17–26].  The 
protozoan is connected with changes in the intestinal tract –referred to as environmental 
enteropathy-- which can alter nutrient intake, lumen barrier function, and risk for repeat 
infection [13,45–48]. These are the extent of known Cryptosporidium infection sequelae, 
but more may present as its epidemiology continues to improve. 
The Global Enteric Multi-center Study 
 Rationale 
The Global Enteric Multi-center Study is the largest case-control study to date 
addressing diarrheal disease etiology. It is a 3-year, prospective, age-stratified, matched 
case-control study of moderate-to-severe diarrhea in children under the age of five from 7 
sites worldwide in sub-Saharan African and South Asia [14]. The study, designed and 
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implemented by the University of Maryland Medical School Center for Vaccine 
Development, was funded in 2006. The goals of this effort are to quantify diarrheal 
disease burden in low-income populations, identify key etiological agents responsible, 
and understand clinical outcomes of interest. In addition to these primary goals, GEMS is 
also intended to guide vaccine development, identify risk factors for disease, estimate 
economic implications of MSD, and generate a repository of clinical specimens for 
continuing research and collaboration.  
Study Population and Design 
The design of the GEMS study is published in detail elsewhere, but in brief, 
GEMS set up a population census at sites meeting basic health care and laboratory 
criteria in Kenya, Mali, Mozambique, the Gambia, Bangladesh, India, and Pakistan [49]. 
Cases were identified through the local health care facility if they had three or more 
abnormally loose stools within 24 hours, and one or more of the following: sunken eyes, 
loss of normal skin turgor, a decision to initiate intravenous hydration, dysentery, or a 
clinical decision to hospitalize the child. One or more controls were matched from within 
the same community if they did not have symptoms of diarrhea with seven days of the 
case enrollment. At enrollment, caretakers of both cases and controls completed an 
interview. All subjects underwent anthropometric measurements and clinical 
observations, and provided stool samples. Caretakers were given a chart to track diarrhea 
(or lack thereof) for two weeks, which was reviewed at a 60-day follow-up visit. The 
follow-up visit also included physical examinations and surveys.  
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Sample Processing 
GEMS stool samples were analyzed using a set of comprehensive microbiological 
assays, standardized across all study sites, as described in detail by Panchalingham, et al 
[50]. The protocols for pathogen detection in GEMS analysis were selected based on the 
performance and robustness of the test, cost effectiveness, and the counsel of respected 
experts in the field for each organism. Enterobacteriaceae, Vibrio spp., Aeromonas spp., 
Campylobacter spp., and E.coli were identified using culture based and biochemical 
techniques. E.coli was further classified using PCR. Rotavirus, adenovirus, and the three 
parasites: Cryptosporidium spp., Giardia enterica, and Entamoeba histolytica, were all 
identified by respective immunoassays. RNA viruses were detected by multiplex PCR.  
Interaction Analysis 
Co-infecting microbes can interact in a number of ways to affect disease 
morbidity and mortality. Biological interaction occurs when two factors, organisms in 
this case, behave differently in combination than they do individually. This process can 
be due to direct interaction or indirectly through changes in the host environment via 
resource use or host immune response [51]. If an outcome associated with co-infection by 
two pathogens (P1 and P2, say) does not occur in individuals with no infection or only P1 
or only P2, the pathogens interact in some way mechanistically [52]. The epidemiological 
groundwork for identifying biological interaction was led by Rothman, who established 
the conditions of “sufficient cause” and applied them to interaction theory [53,54]. This 
mechanistic interaction, or what is actually occurring biologically, is measured 
statistically in a number of ways.  
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Statistical interaction does not necessarily indicate mechanistic interaction, but 
can be used to identify potential biological relationships. Two scales are often employed 
to study interaction: additive and multiplicative. The additive scale shows the difference 
between the risk of outcome with simultaneous infection and the risks with either alone. 
The multiplicative scale shows how risk with dual infection relates to the product of risk 
with single infections. While the additive scale is generally more informative for 
identifying mechanistic interaction, the multiplicative scale is used far more commonly 
due to ease of analysis (regression analysis with interaction provides measure of 
multiplicativity) [52]. For case-control studies, odds ratios are used to show interaction 
on either scale. Sometimes called Relative Excess Risk due to Interaction (RERI), this is 
calculated as ORii −  ORio − ORoi + 1. Standard error and confidence intervals for RERI 
can be calculated using Hosmer Lemeshow’s delta method [55]. The multiplicative scale 
interaction analysis is equal to the odds ratio reported from the interaction term in a 
regression model. For the sake of simplicity, this quotient will be referred to as “MR”, 
and can be understood as ORii (ORio ∗ ORoi⁄ ). Standard error for this number is the same 
as produced in the model. Because the two scales are different measures of interaction, it 
is possible to have a positive additive interaction and negative multiplicative, or vice 
versa.  
Existing Knowledge 
While there is a large collection of research regarding interacting polymicrobial 
infections in a number of body systems, the gastro-intestinal tract has not been a major 
focus of this canon. As mentioned earlier, diarrheal infections with multiple pathogens 
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have been observed in several studies [30–37], and were found in 45% of cases of MSD 
in GEMS [11]. These papers did not further delineate polymicrobial infections by 
organism, so it is unknown what portion of mixed infections contains Cryptosporidium. 
In chickens, a number of in vitro studies have identified interaction between 
Cryptosporidium baileyi and certain immunosuppressant viruses of veterinary 
importance. Especially when pre-exposed to the viruses, Cryptosporidium-virus co-
infections are worse than either infection alone for both morbidity and mortality [56–58]. 
The parasite in chickens is normally asymptomatic.  
In humans, three studies have considered the interaction between 
Cryptosporidium and other enteric pathogens thus far. The first, by Bilenko, et al was 
based on a cohort of 238 Bedouin children followed from birth to 18-23 months of age 
[32]. Using several markers of illness to generate a severity score for diarrheal episodes, 
they compared severity of single infections to severity of Giardia with other co-occurring 
pathogens. Cryptosporidium and Giardia co-infections did not have higher severity 
scores than either pathogen alone. While their results showed no interaction, this was 
based on only 35 samples with Giardia alone, 22 samples with Cryptosporidium alone, 
and 4 samples with both co-occurring.  
The second study, by Lindsay, et al was based on diarrhea cases reporting to a 
large infectious disease hospital in Kolkata, India [59]. This work related the proportions 
of pathogens in polymicrobial diarrhea cases to the proportions of pathogens in all 
diarrhea cases. If no interaction occurred between pathogens, they would expect the 
microbial compositions of single and mixed infections in their study population to be the 
same. This was not the case, and they noted several potential interactions. They focused 
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on Vibrio cholerae and rotavirus, and reported the odds ratio of observed co-occurrence 
of either with various other pathogens relative to what co-occurrence frequency would be 
expected based on single infection frequencies. For V. cholerae, most co-infecting 
pathogens exhibited a negative association, including Cryptosporidium, which was 2.44 
times less likely to be found in V. cholerae positive stools than in V. cholerae negative 
stools. However, after adjusting for age, gender, season, residence, and religion, this 
association was only significant for females. Cryptosporidium was significantly 
positively associated with rotavirus, and after adjustments, was 1.64 times more likely to 
be found in rotavirus-positive stools than in rotavirus negative stools. These relationships 
may point to possible interaction, but could also be the result of either pair originating 
from the same environmental sources.  
The third study, by the same author, used direct additive and multiplicative 
measures of interaction [60]. The focus of this paper was Shigella spp., and GEMS 
formed the study population. They performed additional genetic testing on GEMS stools, 
and used levels (high or low) of the marker ipaH gene in order to quantify the degree of 
Shigella colonization. Cryptosporidium was among the many pathogens tested for 
interaction with Shigella in this analysis. No interaction was found for Cryptosporidium, 
or any pathogen. Of all pathogens studied, Cryptosporidium did have the smallest p-value 
for the multiplicative regression (p=0.16). Shigella did interact negatively with members 




Gaps in Knowledge 
To our knowledge, no study has tested Cryptosporidium against a range of co-
infecting organisms for potential interactions to date. The organism was included as a co-
occurring pathogen in three studies, described above. One paper used direct additive and 
multiplicative interaction measures.   
Project Objectives 
 In this study we use GEMS data to compare microbial identity data from case and 
control stools to evaluate whether Cryptosporidium interacts with other microorganisms, 











Chapter 3: Impact of Cryptosporidium spp. interaction with co-
occurring microorganisms on moderate-to-severe diarrhea in the 
developing world 
Abstract 
 Diarrheal illness is responsible for over a quarter of all deaths in children under 5 
years of age in sub-Saharan Africa and South Asia. Recent findings have pointed to the 
parasite Cryptosporidium as a substantial contributor to enteric disease burden in the 
developing world. We assessed whether Cryptosporidium interacted with any other co-
occurring pathogen in the Global Enteric Multicenter Study (GEMS). We examined 33 
pathogens detected in stools from 9,348 cases and 13,128 controls from The Gambia, 
Kenya, Mali, Mozambique, India, Bangladesh, and Pakistan. Analysis for multiplicative 
and additive interaction was completed using R version 3.2.1, based on calculated odds of 
moderate-to-severe diarrhea (MSD) adjusted for site, age, sex, body mass index (BMI), 
antibiotic use, and stool consistency. Cryptosporidium was found to interact negatively 
with Shigella spp., with multiplicative interaction score of 0.16 (95% CI: 0.07 to 0.37, p-
value=0.000), and an additive interaction score of -9.81 (95% CI: -13.61 to -6.01, p-
value=0.000). Cryptosporidium also interacted negatively on both the multiplicative and 
additive scales with Aeromonas spp., Adenovirus 40/41, Norovirus, and Astrovirus, with 
marginally significant p-values of less than .15. Odds of MSD for Cryptosporidium co-
infection with Shigella spp., Aeromonas spp., Adenovirus 40/41, Norovirus, or Astrovirus 
are lower than odds of MSD with either organism alone. Intervention strategies targeted 
at Cryptosporidium in regions with high incidence of any of these organisms, especially 
Shigella spp., may be less effective than they would be if Cryptosporidium did not 
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interact. The ability of Cryptosporidium to interact with additional organisms to moderate 
diarrhea outcomes may impact the efficacy of targeted intervention strategies and should 




Diarrhea is the second leading cause of death in young children worldwide [1]. 
Diarrheal illness is responsible for 25-30% of all deaths in children under 5 years of age 
in sub-Saharan Africa and South Asia [2]. With time and resources, diarrhea in children 
is easily treatable, but in the developing world, malnutrition and healthcare access issues 
potentiate its harm. Diarrhea in children is also associated with long term developmental 
impacts including growth stunting, cognitive impairments, changes in school 
performance, and work life productivity [3–10]. One of the many microorganisms 
associated with diarrhea in children is the parasite Cryptosporidium spp., and this 
organism is particularly linked to these long term adverse outcomes [7,17–26].  
Public health awareness of the burden and impact of Cryptosporidium has 
veritably exploded in the past three years following the publication of two landmark 
international studies: the Global Enteric Multicenter Study (GEMS) and the Interactions 
of Malnutrition & Enteric Infections: Consequences for Child Health and Development 
(“MAL-ED”) cohort study [14,15]. In GEMS, the parasite was the second leading cause 
of moderate-to-severe diarrhea in infants at five of seven sites in sub-Saharan Africa and 
South Asia, and the overall fraction of illness attributable to Cryptosporidium at all sites 
was far higher than anticipated [11]. In MAL-ED, it was the fifth-leading cause of 
diarrhea in subjects in the first year of life [38]. The new reports of the high burden of 
Cryptosporidium in children of the developing world, in combination with the strong link 
between Cryptosporidium and increased morbidity associated with diarrhea illustrate a 
daunting global health challenge. 
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Putative pathogens, such as Cryptosporidium, are not necessarily detectable in all 
instances of diarrhea: 27% of moderate-to-severe diarrhea (MSD) cases had no 
identifiable pathogen in recent findings [11].  Pathogen detection also doesn’t strictly 
translate to disease: 72% of healthy controls in the same study had one or more pathogens 
detectable [11]. Asymptomatic infection is a public health concern in its own right, as 
infection with enteric pathogens – regardless of diarrhea outcome- is associated with 
environmental enteropathy: subtle changes in the intestinal composition and gut 
microbiota that can impact nutrient intake and enteric illness risk long term [12,13]. 
These complexities limit public health understanding of the scope and burden of enteric 
illness. 
A number of epidemiological studies have identified individuals with two or more 
putative pathogens in diarrhea study populations throughout the world [30–37]. In the 
GEMS, two or more putative pathogens were detected in 45% of children with MSD, and 
32% of controls [11]. This finding is mirrored by more recent results from the MAL-ED 
cohort study, in which two or more pathogens were identified in 41.0% and 29.0% of 
stools for cases and controls, respectively [38]. Organisms in polymicrobial infections 
can interact to alter disease outcomes. For example, Chonmaitree et al. showed that viral 
respiratory tract infections negatively impact clinical outcomes in acute otitis media, a 
common bacterial inner-ear infection [61]. However, few studies have explored whether 
co-infection with Cryptosporidium influences diarrheal disease outcomes in children. 
Here, we explored the possible impacts of co-infection by Cryptosporidium with other 
putative enteric pathogens on diarrheal outcomes in the GEMS case-control study.  
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Materials and Methods 
 GEMS Methods Overview 
The design of the GEMS study is published in detail elsewhere, but in brief, 
GEMS set up a population census at sites meeting basic health care and laboratory 
criteria in six sites within Sub-Saharan Africa and South Asia [49]. Cases were identified 
through the local health care facility if they had three or more abnormally loose stools 
within 24 hours, and one or more of the following: sunken eyes, loss of normal skin 
turgor, a decision to initiate intravenous hydration, dysentery, or a clinical decision to 
hospitalize the child. One or more controls were matched from within the same 
community if they did not have symptoms of diarrhea within seven days of the case 
enrollment. All subjects underwent anthropometric measurements and clinical 
observations, and provided stool samples. 
GEMS stool samples were analyzed using a set of comprehensive microbiological 
assays, standardized across all study sites, as described in detail by Panchalingham, et al 
[50]. The protocols for pathogen detection in GEMS analysis were selected based on the 
performance and robustness of the test, cost effectiveness, and the counsel of respected 
experts in the field for each organism. Enterobacteriaceae, Vibrio spp., Aeromonas spp., 
Campylobacter spp., and Escherichia coli were identified using culture based and 
biochemical techniques [50]. Escherichia coli was further classified to subgroups, 
enterotoxigenic Escherichia coli (ETEC), heat-stable (ST-) ETEC, both typical and 
atypical enteropathogenic Escherichia coli (atyp-EPEC or typ-EPEC), and 
enteroaggregative Escherichia coli (EAEC) using PCR [50]. Rotavirus, adenovirus 
(including serotypes 40 and 41 combined), and the three parasites: Cryptosporidium spp., 
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Giardia enterica, and Entamoeba histolytica, were all identified by respective 
immunoassays [50]. RNA viruses were detected by multiplex PCR, including two 
genotypes for Norovirus (GI and GII) [50].  
The Cryptosporidium test that was used is an enzyme-linked immunosorbent 
assay (ELISA) that identifies Cryptosporidium cyst antigens from stool specimens and is 
commercially available from TechLab, Inc. The assay is 98.4% sensitive and 100% 
specific [62], and has been validated and optimized in a number of studies [63–65]. 
Statistical Analysis 
 For this analysis, data from all GEMS participants from The Gambia, Kenya, 
Mali, Mozambique, India, Bangladesh, and Pakistan was used. Statistical analysis was 
completed using R 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria)[66]. 
Adjusted odds ratios for each pathogen co-infection with Cryptosporidium and another 
organism were calculated using logistic regression models including the following 
covariates: country, study site, age in months, sex, body mass index, and whether the 
subject was on antibiotics when enrolled. Relative Excess Risk due to Interaction (RERI), 
was calculated as ORii −  ORio − ORoi + 1. Standard errors and confidence intervals for 
RERIs were calculated using Hosmer Lemeshow’s delta method [55]. The multiplicative 
scale interaction was derived using a logistic regression model with an interaction term 
containing the results of the Cryptosporidium assay and the additional microbe of 
interest. This measure of departure from multiplicativity, “MR”, can be understood as 
ORii (ORio ∗ ORoi⁄ ). Table 1 summarizes formulas used for this analysis and their 
interpretation. Pathogens whose incidence in combination with Cryptosporidium was 
fewer than 5 for either cases or controls were not included in the analyses.  
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A function for computation of the additive and multiplicative interaction was 
adapted from the Gene-Environment and Gene–Gene Interaction Research Application 
(GEIRA)[67]. The new function, called Co-Infection Interaction Research Application 
(CIIRA) incorporates multiple covariates and also reports MR and RERI, as well as 
incidence measures and general results of the regression model in addition to the previous 




 Interaction analysis was completed for a total of 22,568 subjects (9,348 cases and 
13,128 controls) from The Gambia, Kenya, Mali, Mozambique, India, Bangladesh, and 
Pakistan. Demographic data are presented in Table 2. Multiple organisms were detected 
in 63.2% of all subjects, and statistically significantly different proportions in controls 
and cases (58.7% and 69.4% respectively, p-value= .000).  
Screening co-infection by Cryptosporidium and 32 other pathogens of interest 
was conducted through the CIIRA function. Table 3 illustrates unadjusted incidences for 
the seventeen most common organisms by co-infection incidence in cases. 24 organisms, 
when paired with Cryptosporidium, had sufficient incidences in cases and controls to 
conduct multiplicative and additive analysis. This was conducted using odds ratios 
adjusted for country, study site, age in months, sex, body mass index, stool consistency, 
and antibiotic status. The 24 organisms, by incidence of co-infection in cases, were 
Vibrio spp., Escherichia coli, Giardia, EAEC, Rotavirus, Campylobacter spp., 
Campylobacter jejuni, ETEC, atyp-EPEC, typ-EPEC, ST-ETEC, Shigella spp., 
Norovirus, Adenovirus, Entamoeba histolytica, Norovirus GII, Aeromonas spp., Shigella 
flexneri, Sapovirus, Astrovirus, Norovirus GI, Shigella sonnei, Adenovirus 40/41, and 
Campylobacter coli. Results of the multiplicative and additive analysis for these 
organisms are presented in Table 4. 
Cryptosporidium and Shigella spp. co-infection showed significant negative 
interaction on the multiplicative and additive scales, with an MR of 0.16 (95% CI: 0.07 to 
0.37, p-value=0.000), and a RERI of -9.81 (95% CI: -13.61 to -6.01, p-value=0.000). 
Within Shigella, the two species, flexneri and sonnei, negatively interacted similarly with 
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Cryptosporidium. Shigella flexneri interacted with Cryptosporidium with an MR of 0.16 
(95% CI: 0.06 to 0.58, p-value=0.004), and a RERI of -10.84 ((95% CI: -16.84 to -4.83, 
p-value=0.000). Shigella sonnei interacted with Cryptosporidium with an MR of 0.11 
(95% CI: 0.03 to 0.43, p-value=0.001), and a RERI of -6.79 ((95% CI: -10.49 to -3.10, p-
value=0.000). Shigella spp. was the only organism to significantly interact with 
Cryptosporidium, though four additional organisms interacted with marginal significance. 
Aeromonas spp., Adenovirus 40/41, Norovirus, and Astrovirus all expressed negative 
interaction with Cryptosporidium on both the multiplicative and additive scales, with p-




 This study considers the impact of Cryptosporidium interaction with other co-
occurring organisms on diarrhea outcomes in children of the developing world using data 
from the GEMS case control study. In the participants used for this analysis, we found 
that Cryptosporidium does interact significantly with the Shigelloids, in particular 
Shigella flexneri and sonnei on multiplicative and additive scales. This is the first report 
of Cryptosporidium interacting with another co-occurring organism in a human case-
control study.  
 Cryptosporidium and Shigella spp. showed a negative multiplicative and additive 
interaction. Findings from Lindsay, et al 2015 suggest that these organisms may interact, 
though these were drawn from a smaller GEMS subset and were marginally significant 
on the multiplicative scale with the p-value of 0.16 (MR not reported), and not significant 
on the additive scale with a RERI of -.27 (95% CI: 4.27 to 3.73, p-value=0.91) [60]. 
The marginal significance of the Shigella-Cryptosporidium interaction in the Lindsay 
analysis agrees with our findings, and the differences in values may be explained by the 
different sample sizes, as well as our additional inclusion of BMI, antibiotic status, and 
stool consistency in our logistic regression.  
 This negative interaction is highly significant, though its biological explanation is 
not clear. It is possible that either Cryptosporidium or Shigella spp. interact 
antagonistically within the host environment [51,68], for example by changing intestinal 
binding surface or by competing for similar resources. Further analyses should 
investigate Cryptosporidium-Shigella interaction further to determine if this may have a 
mechanistic explanation, and consider possible biological causes.  
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 In addition to the interaction with Shigella spp., Cryptosporidium showed 
marginal interaction on both the additive and multiplicative scales with Aeromonas spp., 
Adenovirus 40/41, Norovirus, and Astrovirus. These potential interactions also warrant 
further exploration for biological mechanisms and other covariates that may moderate the 
relationships.  
Future work should consider the quantity of Cryptosporidium and any other 
pathogens included as a more accurate measure of exposure to determine whether this 
impacts interaction. Also important may be measures of disease morbidity, which are 
available for some subsets of the GEMS data. It is possible that interaction impacts 
factors like disease duration, type of diarrhea, wasting and a number of other outcomes. 
In studies of Cryptosporidium baileyi interaction with co-infecting viruses in chickens, 
pre-exposure to the virus increased severity of illness [56–58]. Potentially illuminating 
research may regard pre-exposure to either organism to determine if exposure order is 
significant in the Cryptosporidium co-infection interaction in humans. 
Public Health Implications 
While further work should is need to assess the potential for mechanistic 
interaction between Cryptosporidium and Shigella spp. and the other marginally 
significant organisms, knowledge of these negative interactions may inform intervention 
strategies. As Cryptosporidium was so recently recognized as a major contributor to 
global diarrheal disease burden, efforts to reduce enteric illness are now considering 
Cryptosporidium specific interventions. In areas with high incidence of Shigella spp. and 
the other organisms, however, reducing Cryptosporidium alone could exacerbate the 
effects of these pathogens. The odds of presenting with MSD when co-infected are 
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smaller than the odds of presenting with MSD when singularly infected. In these cases, 
Cryptosporidium may not be an ideal candidate for targeted interventions. Knowing the 
negative interaction of Cryptosporidium with other organisms may help public health 
organizations determine how specific their interventions may need to be.   
Limitations 
This study is a brief look into interaction between co-infecting organisms in 
enteric disease, but our findings must be interpreted with caution. Statistical interaction 
does not prove mechanistic interaction, and so further investigation is required before any 
biological relationship is determined.  
Additionally, our outcome of interest was simple MSD diagnosis, but more subtle 
interactions may be identified using additional measures of illness like disease severity, 
prolongation, or other morbidities. Similarly, our organisms were classified by presence 
or absence in stool, but a number of studies have found that pathogen quantity in stool is 
a stronger predictor of disease than simple binary detection [60,69,70]. As interaction, 
especially for parasites, is often a product of resource competition [51], pathogen quantity 
may be paramount.  
Conclusions 
While the statistical interaction that we observed for Cryptosporidium and 
Shigella spp. does not prove mechanistic interaction, the results do suggest that 
interaction with the parasite may moderate odds of MSD in children. Because co-
infection with this pair appears to reduce odds of MSD relative to single infections, this 
negative interaction with Cryptosporidium may limit the efficacy of enteric illness 
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interventions targeted at the parasite specifically, especially if the region has a high 
incidence of shigellosis. The other potential interactions between Cryptosporidium and 
Aeromonas spp., Adenovirus 40/41, Norovirus, and Astrovirus may further reduce the 
efficacy of Cryptosporidium-specific interventions. It is clear that Cryptosporidium is a 
subtly complex microbe whose role in the global burden of enteric illness is growing in 
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 Equation  Notes 
MR   ORii (ORio ∗ ORoi)�   
MR>1 -positive multiplicative interaction                                       
MR<1 -negative multiplicative interaction 
RERI  ORii −  ORio − ORoi + 1  
RERI>0 -positive additive interaction                                    
RERI<0 -negative additive interaction 
RERI Std. 
Error 
√(ORio2 ∗ vario) + (ORoi2 ∗ varoi) + (ORii2 ∗ varii) + (2 ∗  ORio  ∗ ORoi ∗ cov12)
+ (2 ∗ ORio ∗ ORii ∗ cov23) + (2 ∗ ORoi ∗ ORii ∗ cov13) 
From Hosmer Lemeshow, 1992 
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Table 2 
Demographic Information for GEMS Study Population 
 
  Cases Controls 
  n=9440 n=13129 
  # (%) n (%) 
Sex 
    Male 5345 (57) 7478 (57) 
Female 4095 (43) 5651 (43) 
Age Group (months) 
    0-5 1256 (13) 1534 (12) 
6-11 2774 (29) 3343 (25) 
12-23 3205 (34) 4382 (33) 
24-35 1310 (14) 2378 (18) 
36-59 895 (9) 1492 (11) 
Country 
    The Gambia 1029 (11) 1569 (12) 
Mali 2033 (22) 2064 (16) 
Mozambique 682 (7) 1296 (10) 
Kenya 1476 (16) 1883 (14) 
India 1568 (17) 2014 (15) 
Bangladesh 1394 (15) 2465 (19) 






















Unadjusted Incidence of Pathogen and Co-infection With Cryptosporidium  
  Single Infections Co-Infected with Cryptosporidium 
 Organism Cases                     % (#) 
Controls                     
% (#) 
Cases                     
% (#) 
Controls                     
% (#) 
 Cryptosporidium 6.4 (843) 11. 9 (1123) -- -- 
 Vibrio spp. 53.8 (5770) 64.5 (9033) 7.4 (696) 4.3 (565) 
 Escherichia coli 32.8 (3512) 32.3 (4518) 4.4 (419) 2.1 (273) 
 Giardia 16.4 (1786) 24.4 (3470) 2.5 (234) 2.1 (270) 
 EAEC 17.9 (1846) 19.5 (2652) 2.4 (220) 1.2 (157) 
 Rotavirus 16.8 (1747) 3.6 (509) 1.7 (161) 0.2 (30) 
 Campylobacter spp. 10.8 (1171) 11.1 (1562) 1.6 (149) 0.8 (107) 
 Campylobacter jejuni 8.5 (930) 8.1 (1144) 1.3 (127) 0.6 (82) 
 ETEC 10.4 (1066) 7.2 (975) 1.4 (124) 0.4 (55) 
 Atyp-EPEC 7.0 (732) 7.9 (1087) 1.1 (98) 0.6 (72) 
 Typ-EPEC 6.3 (652) 6.6 (908) 0.8 (76) 0.5 (60) 
 ST-ETEC 6.3 (644) 2.7 (364) 0.8 (71) 0.2 (21) 
 Shigella spp. 11.0 (1110) 1.6 (230) 0.7 (69) 0.1 (19) 
 Norovirus 6.9 (722) 6.8 (940) 0.7 (69) 0.4 (51) 
 Adenovirus 3.6 (385) 2.4 (346) 0.5 (48) 0.2 (25) 
 Entamoeba histolytica 2.5 (279) 2.1 (299) 0.5 (47) 0.2 (23) 
 Norovirus GII 4.7 (495) 3.7 (511) 0.5 (47) 0.2 (28) 
 Aeromonas spp. 6.6 (660) 4.5 (620) 0.4 (41) 0.2 (32) 
 Shigella flexneri 7.3 (728) 0.8 (119) 0.4 (41) 0.1 (8) 
 Sapovirus 3.1 (325) 3.3 (456) 0.4 (33) 0.2 (24) 
 Astrovirus 2.2 (238) 1.8 (261) 0.3 (28) 0.2 (21) 
 Norovirus GI 2.5 (265) 3.4 (473) 0.3 (26) 0.2 (27) 
 Shigella sonnei 2.6 (264) 0.5 (71) 0.2 (20) 0.1 (10) 
 Adenovirus 40/41 10.1 (235) 4.1 (98) 0.9 (20) 0.5 (10) 
 Campylobacter coli 1.6 (161) 2.2 (313) 0.1 (11) 0.1 (18) 
 
GI = Norovirus Genotype 1, GII = Norovirus Genotype 2, 40/41 = Adenovirus sero-group 40 or 41, ETEC 
= enterotoxigenic Escherichia coli, ST-ETEC = heat-stable enterotoxigenic Escherichia coli, atyp-EPEC = 
atypical enteropathogenic Escherichia coli, typ-EPEC = typical enteropathogenic Escherichia coli, and 

















Additive Interaction                  
Adjusted RERI 
Organism 2 ORio (95% CI) ORoi (95% CI) Orii (95% CI) MR (95% CI) Pr(>|z|) RERI (95% CI) Pr(>|z|) 
Aeromonas spp. 1.44 (1.21 - 1.71) 2.24 (1.82 - 2.75) 1.55 (0.63 - 3.80) 0.48 (0.19 - 1.21) 0.121 -1.13 (-2.64 - 0.38) 0.141 
Campylobacter spp. 1.36 (1.13 - 1.63) 1.23 (1.06 - 1.43) 1.94 (1.22 - 3.09) 1.16 (0.70 - 1.94) 0.567 0.35 (-0.62 - 1.33) 0.477 
Campylobacter jejuni 1.37 (1.14 - 1.63) 1.39 (1.17 - 1.65) 2.15 (1.27 - 3.63) 1.13 (0.64 - 2.01) 0.666 0.40 (-0.80 - 1.59) 0.517 
Campylobacter coli 1.38 (1.16 - 1.64) 0.81 (0.58 - 1.15) 1.47 (0.37 - 5.92) 1.31 (0.31 - 5.53) 0.711 0.28 (-1.81 - 2.37) 0.793 
Shigella spp. 1.55 (1.30 - 1.84) 12.44 (9.91 - 15.61) 3.17 (1.48 - 6.82) 0.16 (0.07 - 0.37) 0.000 -9.81 (-13.61 - -6.01) 0.000 
Shigella flexneri 1.49 (1.25 - 1.77) 14.16 (10.57 - 18.98) 3.81 (1.24 - 11.67) 0.18 (0.06 - 0.58) 0.004 -10.84 (-16.84 - -4.83) 0.000 
Shigella sonnei 1.43 (1.20 - 1.69) 7.60 (4.90 - 11.81) 1.24 (0.36 - 4.24) 0.11 (0.03 - 0.43) 0.001 -6.79 (-10.49 - -3.10) 0.000 
Vibrio spp. 1.30 (0.96 - 1.75) 0.48 (0.43 - 0.54) 0.71 (0.57 - 0.88) 1.13 (0.78 - 1.62) 0.520 -0.07 (-0.53 - 0.38) 0.752 
Escherichia coli 1.38 (1.12 - 1.69) 1.00 (0.90 - 1.10) 1.40 (1.05 - 1.88) 1.03 (0.72 - 1.47) 0.890 0.03 (-0.51 - 0.58) 0.904 
ETEC 1.38 (1.15 - 1.66) 1.06 (0.89 - 1.26) 1.29 (0.73 - 2.27) 0.88 (0.48 - 1.63) 0.688 -0.15 (-0.96 - 0.66) 0.714 
ST-ETEC 1.38 (1.16 - 1.65) 1.44 (1.13 - 1.84) 1.60 (0.69 - 3.74) 0.80 (0.33 - 1.97) 0.634 -0.22 (-1.66 - 1.22) 0.764 
Typ-EPEC 1.34 (1.12 - 1.60) 1.04 (0.86 - 1.25) 1.95 (1.00 - 3.79) 1.40 (0.69 - 2.86) 0.348 0.57 (-0.77 - 1.92) 0.403 
Atyp-EPEC 1.33 (1.11 - 1.60) 1.02 (0.85 - 1.22) 1.91 (1.04 - 3.49) 1.40 (0.73 - 2.69) 0.313 0.55 (-0.66 - 1.76) 0.371 
EAEC 1.37 (1.13 - 1.66) 0.91 (0.80 - 1.02) 1.22 (0.84 - 1.79) 0.99 (0.64 - 1.52) 0.946 -0.05 (-0.62 - 0.52) 0.856 
Entamoeba histolytica 1.36 (1.14 - 1.61) 1.34 (0.96 - 1.88) 3.14 (1.27 - 7.73) 1.72 (0.65 - 4.56) 0.272 1.44 (-1.45 - 4.33) 0.328 
Giardia 1.37 (1.13 - 1.67) 0.83 (0.74 - 0.94) 1.21 (0.87 - 1.69) 1.06 (0.71 - 1.58) 0.771 0.01 (-0.51 - 0.53) 0.980 
Rotavirus 1.46 (1.23 - 1.74) 3.57 (2.92 - 4.36) 4.84 (2.22 - 10.52) 0.93 (0.41 - 2.10) 0.857 0.81 (-3.06 - 4.67) 0.682 
Adenovirus 1.39 (1.17 - 1.65) 1.26 (0.95 - 1.68) 1.60 (0.69 - 3.71) 0.91 (0.37 - 2.25) 0.842 -0.05 (-1.48 - 1.37) 0.944 
Adenovirus 40/41 1.87 (1.23 - 2.86) 2.57 (1.39 - 4.77) 1.15 (0.29 - 4.57) 0.24 (0.05 - 1.05) 0.058 -2.29 (-4.89 - 0.31) 0.084 
Norovirus 1.44 (1.21 - 1.72) 1.11 (0.92 - 1.34) 0.94 (0.50 - 1.77) 0.59 (0.30 - 1.16) 0.125 -0.61 (-1.31 - 0.09) 0.086 
Norovirus GI 1.41 (1.19 - 1.19) 0.98 (0.75 - 1.30) 0.79 (0.31 - 2.00) 0.57 (0.21 - 1.52) 0.260 -0.60 (-1.43 - 0.23) 0.154 
Norovirus GII 1.42 (1.20 - 1.69) 1.35 (1.07 - 1.71) 1.10 (0.48 - 2.56) 0.57 (0.24 - 1.39) 0.218 -0.67 (-1.70 - 0.35) 0.199 
Sapovirus 1.40 (1.18 - 1.67) 1.03 (0.80 - 1.34) 1.11 (0.47 - 2.63) 0.77 (0.31 - 1.91) 0.570 -0.32 (-1.36 - 0.71) 0.540 
Astrovirus 1.42 (1.19 - 1.68) 1.23 (0.89 - 1.70) 0.77 (0.29 - 2.03) 0.44 (0.16 - 1.24) 0.121 -0.88 (-1.77 - 0.02) 0.054 
 
GI = Norovirus Genotype 1, GII = Norovirus Genotype 2, 40/41 = Adenovirus sero-group 40 or 41, ETEC = enterotoxigenic 
Escherichia coli, ST-ETEC = heat-stable enterotoxigenic Escherichia coli, atyp-EPEC = atypical enteropathogenic Escherichia 
coli, typ-EPEC = typical enteropathogenic Escherichia coli, and EAEC = enteroaggregative Escherichia coli 
ORs adjusted for age, country, site, body mass index, stool consistency, and antibiotic status. 
MR is ORii/(ORio x ORoi), >1 is positive interaction, <1 is negative interaction. 
RERI is ORii – ORio – ORoi +1, >0 is positive interaction, <0 is negative interaction. 
Significant results bolded.
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Chapter 4: Public Health Implications and Conclusions 
Public Health Implications 
 While further work should continue to assess the potential antagonism between 
Cryptosporidium and Shigella spp., this information may inform intervention strategies 
now developing. As Cryptosporidium was so recently recognized as a major contributor 
to global diarrheal disease burden, efforts to reduce enteric illness are now considering 
Cryptosporidium specific interventions. In areas with high incidence of Shigella spp., 
however, reducing Cryptosporidium singularly could exacerbate the effects of these 
pathogens. Knowing the negative interaction of Cryptosporidium with other organisms 
may help public health organizations determine how specific their interventions may 
need to be.    
Concluding Thoughts  
 Future work should consider the quantity of Cryptosporidium and any other 
pathogens included as a more accurate measure of exposure to determine whether this 
impacts interaction. Also important may be measures of disease morbidity, which are 
available for some subsets of the GEMS data. It is possible that interaction impacts 
factors like disease duration, type of diarrhea, wasting and a number of other outcomes. 
As all significant interactions were negative, the possibility of antagonistic interaction 
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